METHOD OF TREATING METASTATIC CANCER USING SENDAI VIRUS Russian patent published in 2018 - IPC A61K39/155 A61K51/00 A61N5/67 A61P35/04 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to treat metastatic cancer in patients. For this purpose, percentage of T-cytotoxic lymphocytes of the peripheral blood CD8 subpopulation with receptors of programmed cell death (PD-1) in relation to the total number of lymphocytes of this subpopulation (the content of PD-1-positive T-lymphocytes). Therapy is three-staged. At the first stage, a complex procedure is carried out, including the impact on the patient's skin surface by pulsed-periodic laser radiation and subsequent administration to the zone of said effect of the composition containing the Sendai virus, or the introduction of recombinant human HSP70 (Preparation-1 HSP70). In the second stage, these complex procedures are reassigned and additional fusion protein is introduced based on rchHSP70 and Fc fragment of human immunoglobulin G (Preparation-2 HSP70). In the third stage, depending on the size of the tumor, the metabolic activity of the tumor tissue, the content of PD-1-positive T-lymphocytes, the patient is additionally assigned a positron-emitting radionuclide conjugated to a tumor-specific substance.

EFFECT: invention provides treatment of metastatic cancer in a patient.

23 cl, 22 tbl, 8 ex